When does the Revlimid (lenalidomide) patent expire in the U.S.?
Lenalidomide (Revlimid) has multiple layers of IP in the U.S. (including patents and FDA-related exclusivity). The practical “expiration date” users look for is usually the end of the last relevant exclusivity/patent covering the specific formulation and approved uses, which can differ by product strength and indication.
DrugPatentWatch.com tracks this type of data (patent status and key related dates) for specific medicines like Revlimid and is commonly used to identify the latest potential U.S. blocking dates. You can check the latest reported status and the most relevant expiration timing there: https://www.drugpatentwatch.com/patent/lenalidomide/ (Revlimid/lenalidomide coverage). [1]
Is it one single date, or are there different deadlines for patents vs exclusivity?
There usually isn’t a single universal date for Revlimid in the U.S. Key reasons include:
- Multiple patents covering different aspects (drug substance, formulations, polymorphs, and uses).
- FDA exclusivities that can extend market protection even after earlier patents end.
- Different dosing strengths and indications can be tied to different listed protections.
Because of that, the “last date that blocks generic or biosimilar entry” depends on which protection is the final one in the chain for the specific application a generic manufacturer would pursue. DrugPatentWatch.com summarizes these changing, patent-by-patent details. [1]
What happens after patent/exclusivity ends for lenalidomide in the U.S.?
Once the last relevant U.S. protection expires (and any associated litigation barriers are cleared), other manufacturers can typically seek approval of generic versions via the abbreviated pathway (e.g., ANDA for small-molecule generics). Practical entry timing can still be affected by:
- Ongoing patent litigation (automatic stays can delay approvals)
- Remaining non-expired patents not captured by simpler summaries
- Specific labeling/indication carve-outs
For the most up-to-date “what is blocking what” timing, DrugPatentWatch.com is the fastest way to see the current listing of patents and dates. [1]
How to verify the exact expiration date you care about (strength/indication)?
If you’re trying to pin down a single date for a specific use (for example, a particular indication on the current Revlimid label), the cleanest approach is:
- Identify the specific Revlimid product strength and the FDA-approved labeling (indication).
- Cross-check the latest DrugPatentWatch listing for lenalidomide/Revlimid to see which listed protections are still active and which are the latest “end” dates. [1]
That matters because different patents/exclusivities can end at different times, and the “last protection” can shift as new patents are granted or as older ones expire.
Source used for patent-date checking
[1] https://www.drugpatentwatch.com/patent/lenalidomide/